What is the recommended management of vaginal candidiasis?

Management of Vaginal Candidiasis

For uncomplicated vaginal candidiasis, prescribe either a single 150 mg oral dose of fluconazole or a short-course (3–7 day) topical azole regimen; both achieve >90% cure rates and are equally effective first-line options. 1, 2

Classification: Uncomplicated vs. Complicated Disease

Before selecting therapy, classify the infection because treatment duration and approach differ substantially:

• Uncomplicated VVC (90% of cases) is defined as sporadic or infrequent episodes (<4 per year), mild-to-moderate symptoms, likely Candida albicans, and occurring in immunocompetent, non-pregnant women. 3, 2
• Complicated VVC (10% of cases) includes severe vulvar inflammation (marked erythema, edema, excoriation, fissures), recurrent episodes (≥3 per year), non-albicans species, uncontrolled diabetes, or immunosuppression. 3, 2

Diagnostic Confirmation Before Treatment

Do not treat empirically without microscopic confirmation—self-diagnosis is accurate in only 30–50% of cases. 1, 2

• Perform wet-mount microscopy with 10% potassium hydroxide to visualize budding yeast or pseudohyphae (sensitivity ≈50–70%). 1, 2
• Measure vaginal pH: pH ≤4.5 supports candidiasis; pH >4.5 suggests bacterial vaginosis or trichomoniasis. 1, 2
• Obtain vaginal culture when microscopy is negative but clinical suspicion remains high, or when symptoms persist after appropriate therapy—culture identifies non-albicans species (especially C. glabrata, which accounts for 10–20% of recurrent cases). 2, 4
• Do not treat asymptomatic colonization (present in 10–20% of women); treatment is not indicated. 1, 2

First-Line Treatment for Uncomplicated VVC

Oral Therapy (Most Convenient)

• Fluconazole 150 mg orally as a single dose is the most convenient regimen and achieves >90% cure rates. 1, 2

Topical Azole Therapy (Equally Effective)

Short-course (3-day) regimens:

• Miconazole 200 mg vaginal suppository once daily for 3 days 1, 2
• Terconazole 0.8% cream 5 g intravaginally once daily for 3 days 1, 2
• Terconazole 80 mg vaginal suppository once daily for 3 days 1, 2
• Clotrimazole 2% cream 5 g intravaginally once daily for 3 days 1

Standard-course (7-day) regimens:

• Clotrimazole 1% cream 5 g intravaginally once daily for 7–14 days 1, 2
• Miconazole 2% cream 5 g intravaginally once daily for 7 days 1, 2
• Terconazole 0.4% cream 5 g intravaginally once daily for 7 days 1, 2

Single-dose topical options:

• Clotrimazole 500 mg vaginal tablet as a single dose 1
• Tioconazole 6.5% ointment 5 g as a single intravaginal application 1

Topical azoles are significantly more effective than nystatin (cure rates 80–90% vs <50%); nystatin should be avoided. 1, 2

Treatment of Complicated (Severe) VVC

When marked vulvar erythema, edema, excoriation, or fissures are present, avoid single-dose regimens. 1, 2

• Extend topical azole therapy to 7–14 days using any of the regimens listed above (clotrimazole 1% cream, miconazole 2% cream, or terconazole 0.4% cream). 1, 2
• Alternative oral regimen: Fluconazole 150 mg orally every 72 hours for a total of 2–3 doses. 2

Management of Recurrent Vulvovaginal Candidiasis (RVVC)

RVVC is defined as ≥3 symptomatic episodes within a 12-month period (updated from the former ≥4-episode threshold). 3, 4

• RVVC affects approximately 9% of women overall, with the highest prevalence (≈12%) in women aged 25–34 years. 3, 4
• Before initiating maintenance therapy, obtain vaginal cultures to confirm species and identify C. glabrata (10–20% of recurrent cases), which is intrinsically resistant to fluconazole. 2, 4

Two-Phase Treatment Strategy for RVVC

Induction Phase (10–14 days):

• Fluconazole 150 mg orally on days 1,4, and 7 (preferred) 4
• OR any topical azole applied daily for 7–14 days (clotrimazole 1% cream, miconazole 2% cream, or terconazole 0.4% cream) 2, 4

Maintenance Phase (6 months):

• Fluconazole 150 mg orally once weekly for 6 months after achieving clinical remission. 2, 4, 5
• This regimen controls symptoms in >90% of patients during treatment, with a disease-free rate of ≈91% at 6 months. 4, 5
• After stopping the 6-month maintenance course, 40–50% of women experience recurrence—counsel patients that RVVC is a chronic condition requiring long-term suppression rather than a definitive cure. 2, 4, 5

Alternative Maintenance Regimens (When Fluconazole Is Contraindicated)

• Clotrimazole 500 mg vaginal suppository once weekly 4
• Ketoconazole 100 mg orally daily (monitor liver enzymes; hepatotoxicity risk ≈1 in 10,000–15,000) 4
• Itraconazole 400 mg orally once monthly 4

Treatment of Non-Albicans Candida Infections

For culture-confirmed Candida glabrata (10–20% of recurrent cases), avoid fluconazole due to intrinsic resistance. 2, 4

• First-line therapy: Boric acid 600 mg intravaginal gelatin capsule once daily for 14 days (achieves ≈70% eradication). 2, 4
• Alternative options:
  • Nystatin 100,000 U vaginal suppository once daily for 14 days 4
  • Topical 17% flucytosine cream ± 3% amphotericin B cream intravaginally nightly for 14 days (for refractory infections) 4
• Extended topical azole therapy (terconazole 0.4% or 0.8% cream for 7–14 days) may be used but yields substantially lower cure rates than for C. albicans. 2

Special Populations

Pregnancy

• Oral fluconazole is contraindicated during pregnancy due to associations with spontaneous abortion and congenital malformations. 1, 2, 4
• Use only 7-day topical azole regimens (clotrimazole 1% cream, miconazole 2% cream, or terconazole 0.4% cream, each 5 g intravaginally daily for 7 days). 1, 2
• Seven-day courses are more effective than shorter regimens in pregnancy. 1
• Boric acid is contraindicated in pregnancy. 2

HIV-Positive Women

• Treatment regimens and clinical response are identical to HIV-negative women; therapy does not need to be altered solely based on HIV status. 2, 4

Uncontrolled Diabetes

• Uncontrolled diabetes classifies infection as complicated, necessitating extended therapy (7–14 days topical or repeated fluconazole dosing). 2

Critical Pitfalls to Avoid

• Do not treat without microscopic confirmation—clinical symptoms overlap significantly with bacterial vaginosis and trichomoniasis. 1, 2
• Do not use single-dose regimens for severe vulvar inflammation; extended 7–14 day therapy is required. 1, 2
• Do not treat asymptomatic colonization (10–20% of women); no therapy is indicated. 1, 2
• Do not routinely treat sexual partners—VVC is not sexually transmitted and partner treatment does not reduce recurrence. 2, 4
• Do not prescribe nystatin—topical azoles are significantly more effective. 1, 2
• Do not start fluconazole maintenance without confirming species by culture—you may be treating resistant C. glabrata. 4
• Oil-based creams and suppositories can weaken latex condoms and diaphragms; counsel patients to avoid concurrent use. 1

When to Obtain Cultures

Obtain vaginal cultures in the following scenarios:

• Microscopy is negative but clinical suspicion remains high 2
• Symptoms persist after appropriate therapy 2
• The patient has ≥3 episodes per year (RVVC) 2, 4
• Prior azole exposure or suspected resistance 4

Cultures enable species identification and antifungal susceptibility testing, essential because non-albicans species show reduced susceptibility to standard azoles. 2, 4

Follow-Up and Re-Evaluation

• Patients should seek further medical evaluation if symptoms persist after completing therapy, recur within 2 months, or if ≥3 episodes occur within a single year. 2, 4
• Schedule regular follow-up visits throughout maintenance therapy to assess efficacy and monitor adverse effects. 4

Emerging Therapies (Not Yet Standard of Care)

• Oteseconazole and ibrexafungerp show promise in clinical trials for azole-resistant VVC but are not yet incorporated into standard treatment algorithms; reserve for refractory cases after specialist consultation. 2, 6
• Probiotics (especially Lactobacillus crispatus) may lower recurrence rates when added to standard therapy, but CDC guidelines continue to endorse azole monotherapy as first-line. 1, 7